SCHEMBL1156569

SCHEMBL1156569

CN(Cc1cc(-c2ccsc2)n(S(=O)(=O)c2cccc(Cl)c2)c1)C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 1/20 0.37
SLC16A1 P53985 1/20 0.37
MCTS1 Q9ULC4 1/20 0.37
RIPK1 Q13546 1/20 0.36
HTR6 P50406 5/20 0.35
FFAR2 O15552 1/20 0.34
BCL9 O00512 1/20 0.34
CTNNB1 P35222 1/20 0.34
AOC3 Q16853 1/20 0.34
STS P08842 1/20 0.34
RORC P51449 3/20 0.34
HTR2C P28335 1/20 0.34
SLC6A4 P31645 1/20 0.34
GLS O94925 1/20 0.34
APAF1 O14727 1/20 0.33
UBE2N P61088 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1157089 0.91 BCL9 (0.35) SLC16A3SLC16A1MCTS1BCL9CTNNB1
SCHEMBL1156664 0.90 SLC16A3 (0.39) SLC16A3SLC16A1MCTS1HTR6BCL9
SCHEMBL1156772 0.88 AOC3 (0.39) RIPK1HTR6FFAR2BCL9CTNNB1
SCHEMBL1156910 0.86 L3MBTL1 (0.39) SLC16A3SLC16A1MCTS1RIPK1HTR6
SCHEMBL1156471 0.86 SLC16A3 (0.34) SLC16A3SLC16A1MCTS1RIPK1HTR2C
SCHEMBL1157093 0.85 SLC1A3 (0.36) SLC16A3SLC16A1MCTS1RIPK1HTR6
SCHEMBL1156570 0.82 LMNA (0.35) SLC16A3SLC16A1MCTS1HTR6BCL9
SCHEMBL1156562 0.82 HTR6 (0.40) RIPK1HTR6STSRORCHTR2C
SCHEMBL30089348 0.82 HTR6 (0.40) RIPK1HTR6STSRORCHTR2C
SCHEMBL1157164 0.80 HTR2C (0.42) HTR6AOC3HTR2CSLC6A4GLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048909-B2 Proton pump inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-01 US disclosed
EP-2336107-A2 Proton pump inhibitors Takeda Pharmaceutical Company Limited (JP) 2011-06-22 EP disclosed
US-20110028476-A1 PROTON PUMP INHIBITORS KAJINO MASAHIRO 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028476-A1 PROTON PUMP INHIBITORS HRH2, HRH4, CYP2C19 SLC16A3 2326/4885SLC16A1 1996/4885MCTS1 4581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.